Infectious Disease Diagnostic Market by Product (Instruments, Reagents & Kits, Software), Sample Type (Blood, Stool, Swab), Testing Type, Pathogen Type, Disease Type, End-User - Global Forecast 2025-2032
Description
The Infectious Disease Diagnostic Market was valued at USD 24.93 billion in 2024 and is projected to grow to USD 27.06 billion in 2025, with a CAGR of 8.88%, reaching USD 49.28 billion by 2032.
Unveiling the Critical Importance of Early Detection and Market Dynamics Driving Innovations in Infectious Disease Diagnostics
The global challenge presented by infectious diseases underscores the critical importance of rapid, accurate diagnostic solutions. Timely identification of pathogens not only informs effective treatment decisions but also underpins public health responses, outbreak containment, and antimicrobial stewardship. Recent experiences with emerging viral threats have highlighted both the advances and persistent gaps in existing diagnostic frameworks, emphasizing the need for adaptable technologies that can deliver precise results across diverse healthcare settings.
Through this executive summary, readers will gain a holistic perspective on the current state of infectious disease diagnostics, exploring technological breakthroughs, regulatory shifts, and market dynamics shaping the industry today. The following analysis weaves together insights on transformative trends, policy impacts, segment-level opportunities, regional nuances, and competitive strategies, all built upon a rigorous research methodology. By synthesizing these elements, strategic decision-makers will be equipped with a nuanced understanding of critical success factors and actionable pathways to enhance diagnostic capabilities in a rapidly evolving landscape.
Exploring the Transformative Technological and Market Shifts Redefining the Infectious Disease Diagnostic Landscape Post-Pandemic
Over the past decade, the diagnostics landscape has undergone a profound transformation driven by technological convergence, digital integration, and shifting clinical demands. Advancements in molecular biology have enabled the development of highly sensitive assays that detect low levels of pathogen genetic material, while immunoassay platforms have become more streamlined and automated. Simultaneously, software-driven analytics and artificial intelligence have emerged as pivotal enablers, allowing rapid interpretation of complex data and supporting real-time decision-making at the point of care.
Moreover, the experience of global health emergencies has accelerated investment in portable, point-of-care testing solutions, fostering partnerships between instrument developers, reagent suppliers, and software innovators. This convergence of capabilities has not only expanded access in decentralized settings but also improved workflow efficiency in central laboratories. Consequently, market stakeholders are rethinking traditional diagnostic pathways, integrating digital reporting, telehealth interfaces, and mobile health applications to bridge gaps between testing sites and clinical endpoints.
Assessing the Cumulative Effects of United States Tariffs on the Infectious Disease Diagnostic Sector Through 2025 and Beyond
In recent years, the United States has implemented a series of tariff measures affecting a wide range of imported diagnostic components and instrumentation. These cumulative levies have introduced new cost pressures on manufacturers and end-users alike, prompting organizations to reevaluate sourcing strategies and supply chain resilience. As import duties have incrementally increased, manufacturers have faced higher input costs for critical reagents, raw materials, and precision components required in molecular and immunoassay systems.
Consequently, companies have responded by diversifying their supplier networks, investing in domestic production capabilities, and exploring tariff mitigation strategies such as free trade zone utilization and reshoring of key manufacturing processes. Healthcare providers and laboratory owners, in turn, are negotiating longer-term contracts and exploring alternative platforms to balance budget constraints with the imperative for diagnostic accuracy and speed. Looking ahead to 2025, this evolving tariff environment will continue to shape competitive dynamics, cost structures, and collaboration models across the diagnostic ecosystem.
In-Depth Market Segmentation Insights Highlighting Product Platforms Sample Matrices Pathogen Classifications and End-User Environments
The market for infectious disease diagnostics is characterized by a diverse range of product platforms, sample matrices, testing modalities, pathogen classifications, disease indications, and end-user environments. Based on product, the market is studied across instruments, reagents and kits, and software solutions. Instruments encompass advanced immunoassay analyzers designed for high throughput, mass spectrometers enabling precise molecular characterization, microarray platforms suited for multiplex analysis, and polymerase chain reaction systems that deliver rapid amplification and detection. Reagents and kits include antigen detection assays capable of identifying pathogen proteins, enzyme-linked immunosorbent assay kits for serological surveillance, immunoassay kits offering targeted antibody detection, and PCR kits optimized for specific genomic targets. Software solutions facilitate data management, algorithmic interpretation, and remote reporting to enhance diagnostic workflows.
Based on sample type, the market is studied across blood, stool, swab, and urine specimens. Blood testing is subdivided into plasma, serum, and whole blood matrices, each requiring tailored processing protocols to ensure analytical fidelity. Swab-based diagnostics include nasal, rectal, and throat sampling approaches, reflecting the need for accessible specimen collection in diverse clinical settings. Urine and stool sampling further broaden the scope of noninvasive testing options. Based on testing type, the market is studied across centralized laboratory testing and point-of-care testing formats, each balancing throughput, turnaround time, and resource requirements. Based on pathogen type, the market is studied across bacterial, fungal, parasitic, and viral categories, with viral diagnostics further delineating assays for hepatitis, HIV, and influenza. Based on disease type, the market is studied across bacterial infectious diseases such as meningitis, pneumonia, and tuberculosis; fungal infections including aspergillosis, candidiasis, and cryptococcosis; parasitic infections like leishmaniasis, malaria, and schistosomiasis; vector-borne diseases encompassing dengue fever, Lyme disease, and Zika virus; and viral infectious diseases including hepatitis variants, HIV/AIDS, and influenza. Based on end-user, the market is studied across academic and research institutes, diagnostic laboratories, and hospitals and clinics, each offering distinct requirements for instrumentation, workflow integration, and regulatory compliance.
Regional Dynamics Shaping Growth of Infectious Disease Diagnostics Across the Americas Europe Middle East Africa and Asia-Pacific
Regional dynamics play a pivotal role in shaping the trajectory of the infectious disease diagnostic market. In the Americas, market participants benefit from a well-established healthcare infrastructure, robust funding mechanisms, and a strong emphasis on research collaborations. These factors drive the adoption of cutting-edge technologies across clinical laboratories and point-of-care settings, while supportive reimbursement frameworks facilitate investment in high-complexity testing platforms.
In Europe, the Middle East and Africa region, regulatory harmonization and cross-border partnerships have accelerated access to innovative diagnostic solutions. Public health initiatives and disease surveillance programs continue to expand, particularly in emerging economies, underscoring the need for scalable testing approaches that can be deployed in both urban centers and remote areas. Collaborative initiatives between governments, non-governmental organizations, and private sector stakeholders are fostering capacity-building efforts that strengthen laboratory networks and enhance readiness for outbreak response.
In the Asia-Pacific region, rapid economic growth and increasing healthcare expenditure are driving significant demand for both laboratory-based and point-of-care diagnostics. Market players are capitalizing on large patient populations and government initiatives aimed at improving rural healthcare access. Localization efforts, including partnerships with regional manufacturers and establishment of local R&D centers, are enabling faster product registration and tailored solution development. Consequently, this region is emerging as a key growth engine for innovative diagnostic technologies.
Competitive Landscape Examination of Industry Leaders Innovators and Collaborative Partnerships Driving Diagnostic Excellence
The competitive landscape of infectious disease diagnostics is defined by a spectrum of established multinational corporations, specialist reagent and kit manufacturers, and innovative software solution providers. Leading instrument developers continue to invest in next-generation platforms that integrate automation with high-throughput capabilities, while reagent suppliers focus on enhancing assay sensitivity and specificity through novel chemistries and proprietary bioreagents. At the same time, software vendors are driving value by delivering cloud-based data analytics, machine learning-powered interpretation, and secure interoperability features to streamline laboratory workflows.
Strategic collaborations and licensing agreements have become commonplace, enabling companies to accelerate product development timelines and expand their geographic reach. Mergers and acquisitions remain a critical lever for scaling operations, augmenting product portfolios, and accessing complementary technological expertise. In parallel, a wave of agile startups is leveraging nimble R&D frameworks to introduce point-of-care innovations and decentralized testing models that challenge traditional paradigms. This dynamic interplay between incumbents and new entrants fosters a fertile environment for technological breakthroughs and market differentiation.
Actionable Strategic Recommendations for Industry Leaders to Navigate Market Complexities and Accelerate Adoption of Advanced Diagnostic Solutions
To capitalize on the evolving opportunities within infectious disease diagnostics, industry leaders should focus on several strategic imperatives. Companies must prioritize integration of digital and AI-driven analytics into diagnostic workflows to enhance result accuracy, reduce interpretation times, and support remote monitoring capabilities. At the same time, diversifying supply chains by forging partnerships with regional manufacturers can help mitigate the impact of tariff fluctuations and ensure continuity of critical reagent and component supplies.
Furthermore, organizations should pursue cross-sector collaborations, aligning with biopharmaceutical developers, healthcare networks, and research consortia to co-create tailored testing solutions that address emerging threats and unmet clinical needs. Investing in talent development, particularly in bioinformatics, data science, and regulatory affairs, will be essential to navigate the complex regulatory environment and accelerate time to market. Finally, expanding presence in high-growth regions through local partnerships and customized go-to-market strategies will enable companies to capture new revenue streams and build resilient, future-proof business models.
Robust Research Methodology Incorporating Primary Interviews Secondary Data Triangulation and Scenario Analyses to Ensure Insights Integrity
This analysis is grounded in a comprehensive research methodology designed to ensure accuracy, reliability, and practical relevance. Primary research included in-depth interviews with senior executives, R&D leaders, and technical experts from diagnostic manufacturers, healthcare institutions, and regulatory agencies. These qualitative insights were complemented by extensive secondary research drawing on peer-reviewed journals, industry white papers, regulatory filings, and conference proceedings.
Data validation was achieved through a structured triangulation process, cross-referencing findings from independent sources to confirm consistency and credibility. Quantitative assessments leveraged a detailed segmentation framework, examining product platforms, sample types, testing modalities, pathogen categories, disease indications, and end-user profiles. Scenario analysis and sensitivity testing were applied to evaluate the potential impact of policy shifts, tariff environments, and regional growth drivers. Throughout the research process, iterative peer reviews and stakeholder consultations ensured alignment with industry best practices and the latest market developments.
Conclusive Perspectives on Evolving Diagnostic Technologies Regulatory Shifts and Strategic Imperatives in Infectious Disease Testing
In conclusion, the infectious disease diagnostic sector stands at the intersection of technological innovation, regulatory evolution, and global health imperatives. Advanced molecular techniques, automation, and AI-powered analytics are redefining diagnostic capabilities, while shifts in trade policies and regional dynamics introduce both challenges and opportunities for market participants. Segmentation analysis reveals a multifaceted landscape where product diversity, sample matrix flexibility, and end-user requirements drive competitive differentiation.
Ultimately, success in this rapidly evolving environment will depend on strategic agility, collaborative partnerships, and a steadfast commitment to quality and accessibility. By aligning investments with emerging trends, mitigating supply chain risks, and harnessing regional growth trajectories, organizations can position themselves to deliver impactful diagnostic solutions that enhance patient outcomes and strengthen global health security.
Please Note: PDF & Excel + Online Access - 1 Year
Unveiling the Critical Importance of Early Detection and Market Dynamics Driving Innovations in Infectious Disease Diagnostics
The global challenge presented by infectious diseases underscores the critical importance of rapid, accurate diagnostic solutions. Timely identification of pathogens not only informs effective treatment decisions but also underpins public health responses, outbreak containment, and antimicrobial stewardship. Recent experiences with emerging viral threats have highlighted both the advances and persistent gaps in existing diagnostic frameworks, emphasizing the need for adaptable technologies that can deliver precise results across diverse healthcare settings.
Through this executive summary, readers will gain a holistic perspective on the current state of infectious disease diagnostics, exploring technological breakthroughs, regulatory shifts, and market dynamics shaping the industry today. The following analysis weaves together insights on transformative trends, policy impacts, segment-level opportunities, regional nuances, and competitive strategies, all built upon a rigorous research methodology. By synthesizing these elements, strategic decision-makers will be equipped with a nuanced understanding of critical success factors and actionable pathways to enhance diagnostic capabilities in a rapidly evolving landscape.
Exploring the Transformative Technological and Market Shifts Redefining the Infectious Disease Diagnostic Landscape Post-Pandemic
Over the past decade, the diagnostics landscape has undergone a profound transformation driven by technological convergence, digital integration, and shifting clinical demands. Advancements in molecular biology have enabled the development of highly sensitive assays that detect low levels of pathogen genetic material, while immunoassay platforms have become more streamlined and automated. Simultaneously, software-driven analytics and artificial intelligence have emerged as pivotal enablers, allowing rapid interpretation of complex data and supporting real-time decision-making at the point of care.
Moreover, the experience of global health emergencies has accelerated investment in portable, point-of-care testing solutions, fostering partnerships between instrument developers, reagent suppliers, and software innovators. This convergence of capabilities has not only expanded access in decentralized settings but also improved workflow efficiency in central laboratories. Consequently, market stakeholders are rethinking traditional diagnostic pathways, integrating digital reporting, telehealth interfaces, and mobile health applications to bridge gaps between testing sites and clinical endpoints.
Assessing the Cumulative Effects of United States Tariffs on the Infectious Disease Diagnostic Sector Through 2025 and Beyond
In recent years, the United States has implemented a series of tariff measures affecting a wide range of imported diagnostic components and instrumentation. These cumulative levies have introduced new cost pressures on manufacturers and end-users alike, prompting organizations to reevaluate sourcing strategies and supply chain resilience. As import duties have incrementally increased, manufacturers have faced higher input costs for critical reagents, raw materials, and precision components required in molecular and immunoassay systems.
Consequently, companies have responded by diversifying their supplier networks, investing in domestic production capabilities, and exploring tariff mitigation strategies such as free trade zone utilization and reshoring of key manufacturing processes. Healthcare providers and laboratory owners, in turn, are negotiating longer-term contracts and exploring alternative platforms to balance budget constraints with the imperative for diagnostic accuracy and speed. Looking ahead to 2025, this evolving tariff environment will continue to shape competitive dynamics, cost structures, and collaboration models across the diagnostic ecosystem.
In-Depth Market Segmentation Insights Highlighting Product Platforms Sample Matrices Pathogen Classifications and End-User Environments
The market for infectious disease diagnostics is characterized by a diverse range of product platforms, sample matrices, testing modalities, pathogen classifications, disease indications, and end-user environments. Based on product, the market is studied across instruments, reagents and kits, and software solutions. Instruments encompass advanced immunoassay analyzers designed for high throughput, mass spectrometers enabling precise molecular characterization, microarray platforms suited for multiplex analysis, and polymerase chain reaction systems that deliver rapid amplification and detection. Reagents and kits include antigen detection assays capable of identifying pathogen proteins, enzyme-linked immunosorbent assay kits for serological surveillance, immunoassay kits offering targeted antibody detection, and PCR kits optimized for specific genomic targets. Software solutions facilitate data management, algorithmic interpretation, and remote reporting to enhance diagnostic workflows.
Based on sample type, the market is studied across blood, stool, swab, and urine specimens. Blood testing is subdivided into plasma, serum, and whole blood matrices, each requiring tailored processing protocols to ensure analytical fidelity. Swab-based diagnostics include nasal, rectal, and throat sampling approaches, reflecting the need for accessible specimen collection in diverse clinical settings. Urine and stool sampling further broaden the scope of noninvasive testing options. Based on testing type, the market is studied across centralized laboratory testing and point-of-care testing formats, each balancing throughput, turnaround time, and resource requirements. Based on pathogen type, the market is studied across bacterial, fungal, parasitic, and viral categories, with viral diagnostics further delineating assays for hepatitis, HIV, and influenza. Based on disease type, the market is studied across bacterial infectious diseases such as meningitis, pneumonia, and tuberculosis; fungal infections including aspergillosis, candidiasis, and cryptococcosis; parasitic infections like leishmaniasis, malaria, and schistosomiasis; vector-borne diseases encompassing dengue fever, Lyme disease, and Zika virus; and viral infectious diseases including hepatitis variants, HIV/AIDS, and influenza. Based on end-user, the market is studied across academic and research institutes, diagnostic laboratories, and hospitals and clinics, each offering distinct requirements for instrumentation, workflow integration, and regulatory compliance.
Regional Dynamics Shaping Growth of Infectious Disease Diagnostics Across the Americas Europe Middle East Africa and Asia-Pacific
Regional dynamics play a pivotal role in shaping the trajectory of the infectious disease diagnostic market. In the Americas, market participants benefit from a well-established healthcare infrastructure, robust funding mechanisms, and a strong emphasis on research collaborations. These factors drive the adoption of cutting-edge technologies across clinical laboratories and point-of-care settings, while supportive reimbursement frameworks facilitate investment in high-complexity testing platforms.
In Europe, the Middle East and Africa region, regulatory harmonization and cross-border partnerships have accelerated access to innovative diagnostic solutions. Public health initiatives and disease surveillance programs continue to expand, particularly in emerging economies, underscoring the need for scalable testing approaches that can be deployed in both urban centers and remote areas. Collaborative initiatives between governments, non-governmental organizations, and private sector stakeholders are fostering capacity-building efforts that strengthen laboratory networks and enhance readiness for outbreak response.
In the Asia-Pacific region, rapid economic growth and increasing healthcare expenditure are driving significant demand for both laboratory-based and point-of-care diagnostics. Market players are capitalizing on large patient populations and government initiatives aimed at improving rural healthcare access. Localization efforts, including partnerships with regional manufacturers and establishment of local R&D centers, are enabling faster product registration and tailored solution development. Consequently, this region is emerging as a key growth engine for innovative diagnostic technologies.
Competitive Landscape Examination of Industry Leaders Innovators and Collaborative Partnerships Driving Diagnostic Excellence
The competitive landscape of infectious disease diagnostics is defined by a spectrum of established multinational corporations, specialist reagent and kit manufacturers, and innovative software solution providers. Leading instrument developers continue to invest in next-generation platforms that integrate automation with high-throughput capabilities, while reagent suppliers focus on enhancing assay sensitivity and specificity through novel chemistries and proprietary bioreagents. At the same time, software vendors are driving value by delivering cloud-based data analytics, machine learning-powered interpretation, and secure interoperability features to streamline laboratory workflows.
Strategic collaborations and licensing agreements have become commonplace, enabling companies to accelerate product development timelines and expand their geographic reach. Mergers and acquisitions remain a critical lever for scaling operations, augmenting product portfolios, and accessing complementary technological expertise. In parallel, a wave of agile startups is leveraging nimble R&D frameworks to introduce point-of-care innovations and decentralized testing models that challenge traditional paradigms. This dynamic interplay between incumbents and new entrants fosters a fertile environment for technological breakthroughs and market differentiation.
Actionable Strategic Recommendations for Industry Leaders to Navigate Market Complexities and Accelerate Adoption of Advanced Diagnostic Solutions
To capitalize on the evolving opportunities within infectious disease diagnostics, industry leaders should focus on several strategic imperatives. Companies must prioritize integration of digital and AI-driven analytics into diagnostic workflows to enhance result accuracy, reduce interpretation times, and support remote monitoring capabilities. At the same time, diversifying supply chains by forging partnerships with regional manufacturers can help mitigate the impact of tariff fluctuations and ensure continuity of critical reagent and component supplies.
Furthermore, organizations should pursue cross-sector collaborations, aligning with biopharmaceutical developers, healthcare networks, and research consortia to co-create tailored testing solutions that address emerging threats and unmet clinical needs. Investing in talent development, particularly in bioinformatics, data science, and regulatory affairs, will be essential to navigate the complex regulatory environment and accelerate time to market. Finally, expanding presence in high-growth regions through local partnerships and customized go-to-market strategies will enable companies to capture new revenue streams and build resilient, future-proof business models.
Robust Research Methodology Incorporating Primary Interviews Secondary Data Triangulation and Scenario Analyses to Ensure Insights Integrity
This analysis is grounded in a comprehensive research methodology designed to ensure accuracy, reliability, and practical relevance. Primary research included in-depth interviews with senior executives, R&D leaders, and technical experts from diagnostic manufacturers, healthcare institutions, and regulatory agencies. These qualitative insights were complemented by extensive secondary research drawing on peer-reviewed journals, industry white papers, regulatory filings, and conference proceedings.
Data validation was achieved through a structured triangulation process, cross-referencing findings from independent sources to confirm consistency and credibility. Quantitative assessments leveraged a detailed segmentation framework, examining product platforms, sample types, testing modalities, pathogen categories, disease indications, and end-user profiles. Scenario analysis and sensitivity testing were applied to evaluate the potential impact of policy shifts, tariff environments, and regional growth drivers. Throughout the research process, iterative peer reviews and stakeholder consultations ensured alignment with industry best practices and the latest market developments.
Conclusive Perspectives on Evolving Diagnostic Technologies Regulatory Shifts and Strategic Imperatives in Infectious Disease Testing
In conclusion, the infectious disease diagnostic sector stands at the intersection of technological innovation, regulatory evolution, and global health imperatives. Advanced molecular techniques, automation, and AI-powered analytics are redefining diagnostic capabilities, while shifts in trade policies and regional dynamics introduce both challenges and opportunities for market participants. Segmentation analysis reveals a multifaceted landscape where product diversity, sample matrix flexibility, and end-user requirements drive competitive differentiation.
Ultimately, success in this rapidly evolving environment will depend on strategic agility, collaborative partnerships, and a steadfast commitment to quality and accessibility. By aligning investments with emerging trends, mitigating supply chain risks, and harnessing regional growth trajectories, organizations can position themselves to deliver impactful diagnostic solutions that enhance patient outcomes and strengthen global health security.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
180 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising need for rapid diagnostics for early detection of infectious diseases
- 5.2. Adoption of AI-driven predictive analytics optimizing outbreak surveillance and response strategies
- 5.3. Increasing demand for rapid antigen screening in airports and public venues enhancing community safety
- 5.4. Expansion of point-of-care multiplex assays driving decentralized infectious disease testing accessibility
- 5.5. Integration of CRISPR-based diagnostics streamlining rapid pathogen detection workflows
- 5.6. Expansion of telehealth-linked diagnostic platforms accelerating remote infectious disease management
- 5.7. Advancements in next-generation sequencing enabling comprehensive pathogen identification in clinical labs
- 5.8. Shift toward at-home molecular testing kits empowering patient-centric infectious disease monitoring
- 5.9. Genomic tools powering the new era of infection tracking
- 5.10. Implementation of digital biomarkers and wearable sensors to predict infection onset before symptoms
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Infectious Disease Diagnostic Market, by Product
- 8.1. Instruments
- 8.1.1. Immunoassay Analyzers
- 8.1.2. Mass Spectrometers
- 8.1.3. Microarrays
- 8.1.4. PCR Systems
- 8.2. Reagents & Kits
- 8.2.1. Antigen Detection Kits
- 8.2.2. ELISA Kits
- 8.2.3. Immunoassay Kits
- 8.2.4. PCR Kits
- 8.3. Software
- 9. Infectious Disease Diagnostic Market, by Sample Type
- 9.1. Blood
- 9.2. Stool
- 9.3. Swab
- 9.3.1. Nasal
- 9.3.2. Rectal
- 9.3.3. Throat
- 9.4. Urine
- 10. Infectious Disease Diagnostic Market, by Testing Type
- 10.1. Laboratory Testing
- 10.2. PoC Testing
- 11. Infectious Disease Diagnostic Market, by Pathogen Type
- 11.1. Bacterial
- 11.2. Fungal
- 11.3. Parasitic
- 11.4. Viral
- 11.4.1. Hepatitis
- 11.4.2. HIV
- 11.4.3. Influenza
- 12. Infectious Disease Diagnostic Market, by Disease Type
- 12.1. Bacterial Infectious Diseases
- 12.1.1. Meningitis
- 12.1.2. Pneumonia
- 12.1.3. Tuberculosis
- 12.2. Fungal Infections
- 12.2.1. Aspergillosis
- 12.2.2. Candidiasis
- 12.2.3. Cryptococcosis
- 12.3. Parasitic Infections
- 12.3.1. Leishmaniasis
- 12.3.2. Malaria
- 12.3.3. Schistosomiasis
- 12.4. Vector-borne Infections
- 12.4.1. Dengue Fever
- 12.4.2. Lyme Disease
- 12.4.3. Zika Virus
- 12.5. Viral Infectious Diseases
- 12.5.1. Hepatitis (A, B, C)
- 12.5.2. Hepatitis B & C
- 12.5.3. HIV/AIDS
- 12.5.4. Influenza
- 13. Infectious Disease Diagnostic Market, by End-User
- 13.1. Academic & Research Institutes
- 13.2. Diagnostic Laboratories
- 13.3. Hospitals & Clinics
- 14. Infectious Disease Diagnostic Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Infectious Disease Diagnostic Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Infectious Disease Diagnostic Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Bio-Rad Laboratories, Inc.
- 17.3.2. F. Hoffmann-La Roche Ltd.
- 17.3.3. Abbott Laboratories
- 17.3.4. Adaptive Biotechnologies Corporation
- 17.3.5. Agilent Technologies, Inc.
- 17.3.6. Becton, Dickinson and Company
- 17.3.7. Bio-Techne Corporation
- 17.3.8. bioMérieux SA
- 17.3.9. Boston Scientific Corporation
- 17.3.10. Bruker Corporation
- 17.3.11. Cardinal Health Inc.
- 17.3.12. Danaher Corporation
- 17.3.13. GE HealthCare Technologies Inc.
- 17.3.14. Grifols, S.A.
- 17.3.15. Hologic Inc.
- 17.3.16. Illumina, Inc.
- 17.3.17. Johnson & Johnson Services Inc.
- 17.3.18. Konica Minolta, Inc.
- 17.3.19. Koninklijke Philips N.V.
- 17.3.20. MedMira Inc.
- 17.3.21. Medtronic PLC
- 17.3.22. Merck KGaA
- 17.3.23. Olympus Corporation
- 17.3.24. Perkin Elmer, Inc.
- 17.3.25. Pfizer Inc.
- 17.3.26. Qiagen N.V.
- 17.3.27. Quest Diagnostics Incorporated
- 17.3.28. Siemens Healthineers AG
- 17.3.29. Sysmex Corporation
- 17.3.30. Thermo Fisher Scientific, Inc.
- 17.3.31. Trivitron Healthcare
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
